Literature DB >> 15131023

E1A as a tumor suppressor gene: commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene.

Steven M Frisch1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15131023     DOI： 10.1158/1078-0432.ccr-04-0644

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.

Authors:  H Yamaguchi; C-T Chen; C-K Chou; A Pal; W Bornmann; G N Hortobagyi; M-C Hung
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 2.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

3.  AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Authors:  Maria Victoria Maliandi; Ana Mato-Berciano; Luciano Sobrevals; Gaël Roué; Anabel José; Cristina Fillat
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

Review 4.  Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.

Authors:  Ingo Jordan; Verena Lohr; Yvonne Genzel; Udo Reichl; Volker Sandig
Journal:  Microorganisms       Date:  2013-11-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.